GlassScriptPhysician profile
Willard G Burks
NPI 1619082310
$3,596.11
in general payments reported to CMS, 2019-2025
26 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $243 · 2021: $611 · 2022: $873 · 2023: $804 · 2024: $340 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $903.90 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $626.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $483.83 | 2020-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $428.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.80 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $191.58 | 2019-2022 | |
| Amgen INC. | $167.17 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $69.53 | 2022-2023 | Freestyle Libre 3 |
| Almatica Pharma LLC | $64.45 | 2022-2024 | Loreev Xr |
| Merck Sharp & Dohme LLC | $57.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.38 | 2022-2024 | Eliquis, Camzyos |
| Cvrx, INC. | $31.02 | 2024 | Barostim Neo System |
| Otsuka America Pharmaceutical, INC. | $29.30 | 2021-2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $22.87 | 2021 | |
| Sumitomo Pharma America, INC. | $21.92 | 2023 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $20.49 | 2020 | |
| Amarin Pharma, INC. | $18.14 | 2021 | |
| Mylan Specialty L.P. | $16.09 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.61 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.18 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.03 | 2022 | |
| Lilly USA, LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.